Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof‐of‐Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Samantha Lane und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmacovigilance Sciences, Drug Safety Research Unit, Southampton, UK. Hauptthemen laut MEDLINE: Public Health, Drug-Related Side Effects and Adverse Reactions, Proof of Concept Study. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Removing medicines from market may benefit public health by preventing adverse drug reactions (ADRs), which should be quantified. This study's aim was to identify a model to quantify the impact of medicines' marketing authorisation (MA) withdrawal and revocation in terms of preventing morbidity and mortality.
Methods
MA withdrawals and revocations for safety reasons in France, Germany and/or the United Kingdom between July 2012 and December 2016 were identified for prescription medicines. Annual exposure was estimated for each medicine, using IQVIA Medical Research Data (IMRD)‐France, IMRD‐Germany and IMRD‐UK primary care electronic health record databases. European Medicines Agency records provided reasons for regulatory action for each medicine. Absolute risks of ADRs which led to MA withdrawal were estimated for patients exposed to each medicine by systematic review of quantitative research. Public health impact, expressed as annual number of ADRs avoided, was estimated by modelling exposure and ADR risk.
Results
Four MA withdrawals and two revocations met study inclusion criteria. Each product's usage decreased following MA withdrawal or revocation. Absolute risk for ADRs was 0.1%–41.25%. To estimate impact of each withdrawal or revocation, its average annual exposure within each IMRD population was multiplied by the absolute risk to give the crude number of ADRs prevented annually due to regulatory action.
Conclusions
This model quantifies the public health impact of MA withdrawal and revocation in terms of serious morbidity, resulting from eliminated or reduced usage of medicines. This method can be applied to products in other settings to quantify the impact of other pharmacovigilance actions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Pharmacovigilance Sciences, Drug Safety Research Unit, Southampton, UK.
- Drug Safety Research Unit, Southampton, UK.
- School of Pharmacy & Biosciences, University of Portsmouth, Portsmouth, UK.
ORCID-Profile: Samantha Lane, Elizabeth Lynn, Saad Shakir
Zitieren
APA
Lane, S., Lynn, E., & Shakir, S. (2024). Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof‐of‐Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70003
Vancouver
Lane S, Lynn E, Shakir S. Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof‐of‐Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70003
BibTeX
@article{Lane2024,
author = {Lane, Samantha and Lynn, Elizabeth and Shakir, Saad},
title = {Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof‐of‐Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.70003}
}
EUVIMED